专利号:US-11406709-B2 优先权日:2014-09-15 标 题 :Therapeutic and research application of PDCL3 发明人:RAHIMI NADER 权利人:UNIV BOSTON 摘要:Described herein are novel compositions comprising, for example, PDCL3 polypeptides having VEGFR-2 inhibitory activity, inhibitory PDCL3 antibodies and PDCL3-binding fragments thereof, or PDCL3 inhibitory nucleic acid molecules, and methods of their use in anti-angiogenesis and anti-tumor proliferation and invasiveness therapies, such as the treatment of cancer, as well as the treatment of those vascular diseases where pathological angiogenesis plays a role, such as in carotid artery disease, macular degeneration, and plaque neovascularization. Also described herein are novel compositions comprising engineered PDCL3 polypeptides having enhanced chaperone activity, recombinant cells comprising such engineered PDCL3 polypeptides having enhanced chaperone activity, and methods thereof for therapeutic protein production and in vitro protein synthesis.
1: Strauss M, Leischik R, Jehn U, Padberg JS, Pistulli R, Kümpers P, Reinecke H. Der hypertensive Notfall : Empfehlungen zum initialen medikamentösen Therapiemanagement [The hypertensive emergency situation : Recommendations for initial drug therapy management]. Med Klin Intensivmed Notfmed. 2020 Sep 17. German. doi: 10.1007/s00063-020-00728-6. Epub ahead of print. 21(10):1189-1192. doi: 10.1080/14656566.2020.1732923. Epub 2020 Feb 26. 130:180-190. doi: 10.1016/j.phrs.2018.02.026. Epub 2018 Feb 23. 18(1):3. doi: 10.1186/s12872-017-0722-z. 5: Il'in SA. Urapidil kak preparat vybora dlia snizheniia arterial'nogo davleniia v khirurgicheskoĭ praktike [Urapidil as a drug of choice for decreasing arterial pressure in surgical practice]. Angiol Sosud Khir. 2017;23(4):147-158. Russian. 55(6):723-31. German. doi: 10.1007/s00120-016-0082-9. 73(8):379-82. 54(11):70-4. Russian. doi: 10.18565/cardio.2014.11.70-74. 53(6):66-70. Russian. 53(12):79-82. Russian. 52(8):77-82. Russian. 52(1):86-90. Russian. 52(4):883-9. doi: 10.1016/j.yjmcc.2011.09.017. Epub 2011 Sep 24. 27(7):426-43. doi: 10.1007/s12325-010-0039-0. Epub 2010 Jun 28. 148(8):370-3. Czech. 134(14):701-7. German. doi: 10.1055/s-0029-1208109. Epub 2009 Mar 24. 150(51-52):47-8. German. 126(5):293-8. German. doi: 10.1055/s-2004-820420. 99(9):528-35; quiz 536. German. doi: 10.1007/s00063-004-1079-5. 99(3):718-27, table of contents. doi: 10.1213/01.ANE.0000130589.00098.CD.
合成参考文献
摘要:Oyo Yakuri. Pharmacometrics., 33(453), 1987 摘要:S76 | LUXPHARMA | Pharmaceuticals Marketed in Luxembourg | Pharmaceuticals marketed in Luxembourg, as published by d'Gesondheetskeess (CNS, la caisse nationale de sante, www.cns.lu), mapped by name to structures using CompTox by R. Singh et al. (2021) DOI:10.1021/acsenvironau.1c00008. List downloaded from 参考文献:10.1007/bf00203780|10.1007/s002280050034 摘要:Harada K, Ohashi K, Fujimura A, Kumagai Y, Ebihara A. Effect of α1-adrenoceptor antagonists, prazosin and urapidil, on a finger skin vasoconstrictor response to cold stimulation. European Journal of Clinical Pharmacology. 1996 Feb;49(5):371–5. doi: 10.1007/s002280050034.